| Name | Metixene hydrochloride hydrate |
| Description | Metixene hydrochloride hydrate has potential anticholinergic activity and inhibits the binding of quinine ring benzoate (QNB) to muscarine receptors, with IC50 and Ki values of 55 nM and 15 nM, respectively. Metixene hydrochloride hydrate can be used to prevent and treat Parkinson's disease. |
| In vitro | Metixene hydrochloride hydrate, with IC50 and Ki values of 55 nM and 15 nM, respectively, has the potential to inhibit the binding of QNB with the muscarinic receptor [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 5 mg/mL (13.74 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.5 mM), Sonication is recommended.
DMSO : 70 mg/mL (192.33 mM), Sonication is recommended.
|
| Keywords | Metixene hydrochloride Hydrate | Metixene hydrochloride hydrate | mAChR | Cholinergic |
| Inhibitors Related | Adiphenine hydrochloride | (+)-Sparteine | Ethyl (triphenylphosphoranylidene) acetate | Clozapine N-Oxide | Pilocarpine nitrate | Urethane | Ribavirin | Adenine | Dibucaine | Choline chloride | Propoxur | Pempidine |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Anti-Alzheimer's Disease Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Neurotransmitter Receptor Compound Library | Bioactive Compounds Library Max |
United States
